Various clinical trials have evaluated the clinical value of an initial dose intensification of imatinib in CML-CP patients (an overview of the most important response rates is given in Table 1).

Imatinib is a tyrosine kinase inhibitor widely used in the treatment of chronic myelogenous leukemia. Originally designed to target the chronic-myelogenous-leukemia-specific tyrosine kinase bcr ...

Of the compounds Nick sent me for testing, I identified CGP 57148B (also known as STI571, Gleevec, Glivec or imatinib mesylate) as the most effective at killing CML cells without harming normal ...

Inhibikase Therapeutics ( (IKT) ) has provided an announcement. Inhibikase Therapeutics, Inc. released a new presentation on ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Find all the commercial and brand names of generic drug called Imatinib. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Most employers have little idea what the pharmacy benefit managers they hire do with the money they exchange for the ...

Blood cancer is not always fatal and advancements in treatment offer significant hope. Misconceptions exist, such as it being ...

A key gene that could enhance the treatment success rates of chronic myeloid leukemia (CML) has been discovered by ...

Dr Georgia Papacleovoulou, head of policy and advocacy at Leukaemia UK, said: "Unexplained bruising is one of the symptoms ...

Cogent Biosciences' uncertain competitive edge may compel investors to sit on the sidelines. Read more about the cautious ...

Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...